WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function

Immune checkpoint therapies, such as programmed cell death ligand 1 (PD-L1) blockade, have shown remarkable clinical benefit in many cancers by restoring the function of exhausted T cells. Hence, the identification of novel PD-L1 regulators and the development of their inhibition strategies have sig...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Hyun Ju, Kim, Gi-Cheon, Oh, Sejin, Kim, Hakhyun, Kim, Yong Keon, Lee, Yunji, Kim, Min Seo, Kwon, Gino, Ok, Yeon-Su, Kwon, Ho-Keun, Kim, Hyun Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722663/
https://www.ncbi.nlm.nih.gov/pubmed/36357569
http://dx.doi.org/10.1038/s12276-022-00876-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722663/
https://www.ncbi.nlm.nih.gov/pubmed/36357569
http://dx.doi.org/10.1038/s12276-022-00876-z

Ejemplares similares